ライフサイエンスコーパス: lower respiratory tract

1 ence the distribution of the inoculum in the lower respiratory tract.

2 isease severity and persistence in the swine lower respiratory tract.

3 per respiratory infection progressing to the lower respiratory tract.

4 n links this pathogen with infections of the lower respiratory tract.

5 chanism that limits viral replication in the lower respiratory tract.

6 h is associated with virus attachment to the lower respiratory tract.

7 replication but did prevent infection of the lower respiratory tract.

8 taxa indicating bacteria replicating in the lower respiratory tract.

9 were often clonally related to cells in the lower respiratory tract.

10 imens to check that they originated from the lower respiratory tract.

11 of novel reassortants were isolated from the lower respiratory tract.

12 and spread extensively in both the upper and lower respiratory tracts.

13 elicit IgG in serum and IgA in the upper and lower respiratory tracts.

14 old more than 1129 did in both the upper and lower respiratory tracts.

15 ever, differed greatly between the upper and lower respiratory tracts.

16 o an opportunistic pathogen of the upper and lower respiratory tracts.

17 igher levels than IHD-J-Luc in the upper and lower respiratory tracts.

18 and reduced RSV loads in both the upper and lower respiratory tracts.

19 Of the 20 isolates from blood and the lower respiratory tract, 19 (95%) harbored the R variant

20 ted with a reduced risk of infections of the lower respiratory tract (31.7% vs. 39.1%; hazard ratio,

21 common anatomical site of isolation was the lower respiratory tract (58.8%), followed by superficial

22 d moderately or abundantly to both upper and lower respiratory tract, a pattern not seen before for a

23 for colonization and persistence only in the lower respiratory tract, a site where innate and adaptiv

24 ne avian virus that replicated poorly in the lower respiratory tract, all of the viruses replicated i

25 the vaccine virus does not replicate in the lower respiratory tract, allowing us to assess the prote

26 rotection from challenge in the upper versus lower respiratory tract and bear upon live attenuated va

27 rticle aerosols of virus would penetrate the lower respiratory tract and blanket alveoli where target

28 bition of viral replication in the upper and lower respiratory tract and much reduced viral shedding.

29 mmunity-acquired infections of the upper and lower respiratory tract and potentially increasing morbi

30 H9 viruses infected the upper and lower respiratory tract and the majority of H9 viruses h

31 hibited limited replication in the upper and lower respiratory tract and triggered strong protective

32 The time to first lower-respiratory-tract and gastrointestinal-tract infec

33 nt reduced viral titers, particularly in the lower respiratory tract, and substantially alleviated di

34 nduced by aerosol immunization targeting the lower respiratory tract, and that S-FLU is a promising u

35 replicated extensively in both the upper and lower respiratory tracts, and lung lesions were typical

36 ction against RSV infection in the upper and lower respiratory tract at a dose of 10(6) PFU of vaccin

37 ly defective in replication in the upper and lower respiratory tract but also triggered a strong prot

38 07(ts sig) virus replicated in the upper and lower respiratory tract, but the replication of a reasso

39 Infection of the lower respiratory tract by influenza A viruses results i

40 us clinical syndrome primarily affecting the lower respiratory tract, characterized by episodic or pe

41 important bacterial pathogen associated with lower respiratory tract colonization and with acute exac

42 to-treat infected population, we noted fewer lower respiratory tract complications requiring antibiot

43 linical symptom alleviation, reduces risk of lower respiratory tract complications, and admittance to

44 ized with H1N1pdm09 were more likely to have lower respiratory tract complications, shock/sepsis, and

45 Bacterial infection of the lower respiratory tract contributes to approximately 50%

46 Respiratory syncytial virus (RSV) lower respiratory tract disease (LRD) is a life-threaten

47 e analyses, more patients with 2009 H1N1 had lower respiratory tract disease (LRD), hypoxemia, and pr

48 Viremia increased the risk of progression to lower respiratory tract disease (LRD), hypoxemia, respir

49 ll transplantation (HCT), frequently causing lower respiratory tract disease (LRTD).

50 Lower respiratory tract disease can manifest itself as a

51 upper respiratory tract and then progress to lower respiratory tract disease in a subset of patients.

52 (RSV) is an important pathogen causing acute lower respiratory tract disease in children.

53 al virus (RSV) is the leading viral cause of lower respiratory tract disease in infants and children

54 amyxovirus, is a major viral cause of severe lower respiratory tract disease in infants and children.

55 tial virus (hRSV) is responsible for serious lower respiratory tract disease in infants and in older

56 yncytial virus (RSV) is the leading cause of lower respiratory tract disease in infants and young chi

57 uitous respiratory virus that causes serious lower respiratory tract disease in infants and young chi

58 SV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very

59 The lower respiratory tract disease observed in this monkey

60 g for respiratory viruses (RVs) in suspected lower respiratory tract disease, 72 paired NP and bronch

61 children with acute respiratory failure from lower respiratory tract disease, an extubation readiness

62 diagnostic techniques and is associated with lower respiratory tract disease, particularly in childre

63 syncytial virus (RSV) is a leading cause of lower respiratory tract disease, which causes high rates

64 is a primary etiological agent of childhood lower respiratory tract disease.

65 eceiving invasive mechanical ventilation for lower respiratory tract disease.

66 iratory pathogen that causes acute upper and lower respiratory tract disease.

67 children with acute respiratory failure from lower respiratory tract disease.

68 ons may explain why MERS is characterized by lower respiratory tract disease.

69 (RSV) is the most important cause of severe lower-respiratory tract disease in calves and young chil

70 p disorder, cardiovascular diseases, chronic lower respiratory tract diseases, liver cirrhosis, and s

71 as Haemophilus influenzae, a major cause of lower respiratory tract diseases, must cope with a range

72 and to assess its association with upper and lower respiratory tract disorders.

73 retion was selectively enhanced in the human lower respiratory tract during a seasonal outbreak domin

74 ically cause mild infections in the upper or lower respiratory tract, gastrointestinal tract, or ocul

75 c plasmablasts presumably originating in the lower respiratory tract have recently been found in the

76 om 524 Argentinean infants hospitalized with lower respiratory tract illness (LRTI) due to respirator

77 Viral lower respiratory tract illness (LRTI) frequently causes

78 syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI) in children.

79 RSV) is the most common cause of viral acute lower respiratory tract illness (LRTI) in young children

80 Hospitalizations and deaths due to severe lower respiratory tract illness (LRTI) were recorded dur

81 ildren develop recurrent, severe episodes of lower respiratory tract illness (LRTI).

82 Immune-mediated lung injury is a hallmark of lower respiratory tract illness caused by respiratory sy

83 One hundred and fifty (29%) infants had a lower respiratory tract illness during the first year of

84 Respiratory syncytial virus (RSV) causes lower respiratory tract illness frequently.

85 Early life lower respiratory tract illness impairs lung function at

86 RATIONALE: Lower respiratory tract illness is a major cause of chil

87 Collecting sputum from children with lower respiratory tract illness is feasible and is perfo

88 Preventing early life lower respiratory tract illness is important to optimize

89 mens from participants presenting with acute lower respiratory tract illness or acute febrile illness

90 Lower respiratory tract illness surveillance was perform

91 Lower respiratory tract illness was independently associ

92 of a body temperature above 39 degrees C and lower respiratory tract illness, as compared with the co

93 he impact of early life exposures, including lower respiratory tract illness, on lung function during

94 th confirmed H7N9 virus infection had severe lower respiratory tract illness, were epidemiologically

95 allmark of respiratory syncytial virus (RSV) lower respiratory tract illness.

96 ther OCSs reduce symptom scores during acute lower respiratory tract illnesses (LRTIs) in preschool c

97 ct infections and are associated with severe lower respiratory tract illnesses such as pneumonia and

98 common cold, occasionally with more serious lower respiratory tract illnesses, and frequently with a

99 and protection from virus replication in the lower respiratory tract.IMPORTANCE RSV disease is of gre

100 itionally associated with specimens from the lower respiratory tract in adults.

101 es did not confer complete protection in the lower respiratory tract in either animal model, whereas

102 stent wheeze or asthma and infections of the lower respiratory tract in offspring by approximately 7

103 that is a mucosal pathogen of the upper and lower respiratory tracts in humans.

104 should elicit mucosal immunity at upper and lower respiratory tracts in order to most effectively pr

105 n the upper respiratory tract and not in the lower respiratory tract, including lung.

106 nd these pathogens can be aspirated into the lower respiratory tract, increasing the risk of respirat

107 of hospitalizations for RSV-associated acute lower respiratory tract infection (ALRI) detected by act

108 infant hospitalizations for all-cause acute lower respiratory tract infection (ALRI).

109 ied the epidemiology of RSV-associated acute lower respiratory tract infection (ALRTI) hospitalizatio

110 al virus (RSV) is the leading cause of viral lower respiratory tract infection (LRTI) and hospitaliza

111 that can predict the risk of progression to lower respiratory tract infection (LRTI) and RSV-associa

112 that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that suppor

113 (RSV) upper respiratory tract infection and lower respiratory tract infection (LRTI) but is associat

114 Lower respiratory tract infection (LRTI) commonly causes

115 Distinguishing between bacterial and viral lower respiratory tract infection (LRTI) remains challen

116 cumented pneumonia, and secondary outcome, a lower respiratory tract infection (LRTI) without radiogr

117 r respiratory tract infection (URTI) without lower respiratory tract infection (LRTI), URTI progressi

118 al significance remains unclear in pediatric lower respiratory tract infection (LRTI).

119 e most common reason for hospitalization was lower respiratory tract infection (LRTI).

120 is to 5.84 (95% CI 5.61-6.08; p < 0.001) for lower respiratory tract infection (LRTI).

121 egalovirus (CMV) antigenemia (p = 0.005) and lower respiratory tract infection (p = 0.003) and no leu

122 One patient developed a lower respiratory tract infection after EBUS-TBNA, requi

123 cimens from patients hospitalized with acute lower respiratory tract infection and identified factors

124 ered by elective CS had an increased risk of lower respiratory tract infection and juvenile idiopathi

125 ma, oral corticosteroids, or antibiotics for lower respiratory tract infection and less than 2 puffs

126 rising patients with community-acquired mild lower respiratory tract infection and matched controls o

127 eneralisable, causal association between RSV lower respiratory tract infection and subsequent long-te

128 ne candidates were efficacious in preventing lower respiratory tract infection as well as in reducing

129 Human respiratory syncytial virus (RSV) lower respiratory tract infection can result in inflamma

130 toring of otherwise healthy infants with RSV lower respiratory tract infection could help identify pa

131 yncytial virus (RSV) is the primary cause of lower respiratory tract infection during childhood and c

132 he effects of oral corticosteroids for acute lower respiratory tract infection in adults without asth

133 syncytial virus (RSV) is the major cause of lower respiratory tract infection in children worldwide.

134 is the leading cause of hospitalization for lower respiratory tract infection in children.

135 virus (RSV) is the most significant cause of lower respiratory tract infection in infancy worldwide.

136 ical evidence has been accumulating that RSV lower respiratory tract infection in infants may be link

137 ial virus (hRSV) is a leading cause of acute lower respiratory tract infection in infants, elderly an

138 Acute bronchiolitis is the most frequent lower respiratory tract infection in infants, yet there

139 al virus (RSV) is the most frequent cause of lower respiratory tract infection in infants.

140 yndrome coronavirus (MERS-CoV) causes severe lower respiratory tract infection in people.

141 alog, efficiently inhibits established acute lower respiratory tract infection in the animals, even w

142 We conclude that PVL does not contribute to lower respiratory tract infection in this nonhuman prima

143 syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children worl

144 ry syncytial virus is a major cause of acute lower respiratory tract infection in young children, imm

145 ococcus pneumoniae, the transition to severe lower respiratory tract infection is associated with an

146 Acute lower respiratory tract infection is common and often tr

147 Respiratory syncytial virus (RSV) lower respiratory tract infection is implicated in asthm

148 Acute lower respiratory tract infection is responsible for an

149 and increased dissemination to blood in the lower respiratory tract infection model.

150 multiplier equal to the ratio of the median lower respiratory tract infection mortality rate in each

151 ion for ICU-acquired MRSA infections, either lower respiratory tract infection or bloodstream infecti

152 corticosteroids should not be used for acute lower respiratory tract infection symptoms in adults wit

153 rved for duration or severity of other acute lower respiratory tract infection symptoms, duration of

154 outcomes were duration and severity of acute lower respiratory tract infection symptoms, duration of

155 Progression to lower respiratory tract infection with clinical and radi

156 deficient (PAD) patients, 4 (5%) adults with lower respiratory tract infection, 1 (2.6%) sputum sampl

157 nts judged reasonably related to siltuximab (lower respiratory tract infection, anaphylactic reaction

158 ix [12%]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each t

159 aged >60 yr) patients in health and during a lower respiratory tract infection, community-acquired pn

160 obstruction in smokers, a predisposition to lower respiratory tract infection, higher exacerbation f

161 e in infancy, specifically the occurrence of lower respiratory tract infection, is associated with lo

162 are typically young children with upper and lower respiratory tract infection, presenting with sympt

163 he epithelial secretome participating in RSV lower respiratory tract infection-induced airway remodel

164 nts that resulted in two bacteremias and one lower respiratory tract infection.

165 ed paramyxovirus that causes acute upper and lower respiratory tract infection.

166 /2012, rhesus macaques developed a transient lower respiratory tract infection.

167 tient population but may progress rapidly to lower respiratory tract infection.

168 to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial

169 nfection or bloodstream infection, was poor (lower respiratory tract infection: sensitivity, 24.2%; s

170 moxicillin provides little benefit for acute lower-respiratory-tract infection in primary care both o

171 Lower-respiratory-tract infection is one of the most com

172 benefits and harms of amoxicillin for acute lower-respiratory-tract infection with those of placebo

173 .25]; two studies, 1 681 020 events) and for lower respiratory tract infections (-18.48% [-32.79 to -

174 nfection (343 [45%] infections), followed by lower respiratory tract infections (171 [22%]), gastroin

175 monia among patients hospitalized with acute lower respiratory tract infections (ALRTIs).

176 Lower respiratory tract infections (LRTIs) are a persist

177 ry syncytial virus (RSV) and rhinovirus (RV) lower respiratory tract infections (LRTIs) being strongl

178 se single-stranded RNA virus responsible for lower respiratory tract infections (LRTIs) in humans.

179 per respiratory tract infections (URTIs) and lower respiratory tract infections (LRTIs) was collected

180 0.7%) presented with a severe illness: 2 had lower respiratory tract infections (LRTIs) with low-dens

181 logical pathogen in hospitalized adults with lower respiratory tract infections (LRTIs).

182 We assessed the seasonality of viral lower respiratory tract infections (V-LRI), bacteremic p

183 ory syncytial virus (RSV) is responsible for lower respiratory tract infections and annually results

184 f this test for identification of subsequent lower respiratory tract infections and bloodstream infec

185 Mexico/InDRE4487/2009) resulted in upper and lower respiratory tract infections and clinical disease

186 al virus (RSV) is the leading cause of acute lower respiratory tract infections and hospitalizations

187 spiratory syncytial virus (RSV) causes acute lower respiratory tract infections and is the leading ca

188 dictor for the subsequent occurrence of MRSA lower respiratory tract infections and MRSA bloodstream

189 children hospitalized at one institution for lower respiratory tract infections between January 1, 20

190 Lower respiratory tract infections by respiratory syncyt

191 Lower respiratory tract infections caused by bacteria ar

192 test the hypothesis that PVL contributes to lower respiratory tract infections caused by S. aureus s

193 association study and subsequent symptoms of lower respiratory tract infections during the first year

194 Lower respiratory tract infections from respiratory sync

195 ortant cause of otitis media in children and lower respiratory tract infections in adults with chroni

196 gen that causes otitis media in children and lower respiratory tract infections in adults with chroni

197 mon cause of otitis media in children and of lower respiratory tract infections in adults with chroni

198 al virus (RSV) is a major cause of upper and lower respiratory tract infections in children for which

199 irus (RSV) is the leading etiologic agent of lower respiratory tract infections in children, but no l

200 tial virus (RSV) is a leading cause of acute lower respiratory tract infections in children.

201 syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children.

202 virus (hRSV) is the leading cause of severe lower respiratory tract infections in children.

203 e susceptibility and exaggerated response to lower respiratory tract infections in general rather tha

204 hPIV3, cause the majority of acute upper and lower respiratory tract infections in humans, particular

205 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in infant and elderly

206 irus (RSV) is the most common cause of viral lower respiratory tract infections in infants and childr

207 hRSV is a leading cause of lower respiratory tract infections in infants and young

208 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants, a safe an

209 ed RNA genome viruses, is a leading cause of lower respiratory tract infections in infants, young chi

210 syncytial virus (RSV) can cause devastating lower respiratory tract infections in preterm infants or

211 Lower respiratory tract infections in the first years of

212 sociated with an increased risk of upper and lower respiratory tract infections in the outpatient set

213 nts with non-CF bronchiectasis and 3 or more lower respiratory tract infections in the preceding year

214 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in the very young.

215 RSV is a major cause of serious lower respiratory tract infections in young children and

216 yncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children glo

217 a single-stranded DNA parvovirus that causes lower respiratory tract infections in young children wor

218 is an emerging respiratory virus that causes lower respiratory tract infections in young children wor

219 s the single most important cause of serious lower respiratory tract infections in young children, ye

220 s the single most important cause of serious lower respiratory tract infections in young children, ye

221 s the single most important cause of serious lower respiratory tract infections in young children, ye

222 Human metapneumovirus (HMPV) causes lower respiratory tract infections in young children.

223 avirus 1 (HBoV1), a human parvovirus, causes lower respiratory tract infections in young children.

224 y syncytial virus (RSV) is the main cause of lower respiratory tract infections in young children.

225 99.6% of in-county children hospitalized for lower respiratory tract infections were admitted to Cinc

226 ratory infections (comprising both upper and lower respiratory tract infections with viruses, bacteri

227 nfectious events (SIEs) (gastroenteritis and lower respiratory tract infections) were investigated fo

228 s upper respiratory tract infections, severe lower respiratory tract infections, and exacerbations of

229 sthma, and the secondary end points included lower respiratory tract infections, asthma exacerbations

230 RSV), a human pathogen that can cause severe lower respiratory tract infections, especially in infant

231 erved CD4 cell counts are at higher risk for lower respiratory tract infections, indicating impaired

232 Head and Neck, Upper Respiratory Infections, Lower Respiratory Tract infections, Infections of the Ga

233 e prevention of medically attended RSV acute lower respiratory tract infections.

234 recommendations for targets in children with lower respiratory tract infections.

235 f infants and young children to severe viral lower respiratory tract infections.

236 n 83 hospitalized patients <2 years old with lower respiratory tract infections.

237 se single-stranded RNA virus responsible for lower respiratory tract infections.

238 etiologic association in persons with severe lower respiratory tract infections.

239 ation on the incidence of diarrhea and acute lower respiratory tract infections.

240 ure-positive and culture-negative sepsis and lower respiratory tract infections.

241 e of particular concern in the management of lower respiratory tract infections.

242 ctices, provided data for 6771 patients with lower-respiratory-tract infections (3742 [55.3%]) and up

243 Patients older than 18 years with acute lower-respiratory-tract infections (cough of </=28 days'

244 PV) is a major causative agent of upper- and lower-respiratory-tract infections in infants, the elder

245 ssessed in three murine models of infection: lower respiratory tract (intranasal challenge of 1 x 10(

246 f oropharyngeal or gastric contents into the lower respiratory tract is a common event in critically

247 The secretion of this protease in the human lower respiratory tract is enhanced during influenza.

248 nasal cavities but not those from the human lower respiratory tract limited B. pertussis growth in v

249 who attended the study clinic and had acute lower respiratory tract (LRT) illness.

250 whereas approximately one-third progress to lower respiratory tract (LRT) involvement.

251 sensor kinase, PlrS [for persistence in the lower respiratory tract (LRT) sensor], which is required

252 Comprehensive molecular testing of single lower respiratory tract (LRT) specimens achieved pathoge

253 This tropism of MERS-CoV for the lower respiratory tract may explain the severity of the

254 Progression of these viral infections to lower respiratory tract may prove fatal, especially in H

255 Mucosal immune mechanisms in the upper and lower respiratory tracts may serve a critical role in pr

256 is the largest to examine composition of the lower respiratory tract microbiome in healthy individual

257 In contrast, the depletion of the lower-respiratory-tract mucosal CD4 T cells as measured

258 riants on virus replication in the upper and lower respiratory tract of ferrets, as well as virus ant

259 ulum is optimal for delivery of virus to the lower respiratory tract of ferrets, particularly when ev

260 /13 virus led to productive infection of the lower respiratory tract of guinea pigs.

261 ed the ability of the mutant to colonize the lower respiratory tract of mice.

262 D locus was found to enhance survival in the lower respiratory tract of swine.

263 tes of MERS-CoV replication in the upper and lower respiratory tracts of camels and humans, respectiv

264 lture and viral replication in the upper and lower respiratory tracts of cotton rats.

265 12 cytokines and chemokines in the upper and lower respiratory tracts of ferrets infected with H5N1,

266 ypes replicated efficiently in the upper and lower respiratory tracts of ferrets; however, only MX/72

267 uses replicated efficiently in the upper and lower respiratory tracts of ferrets; however, the clinic

268 eplicated productively in both the upper and lower respiratory tracts of guinea pigs, similarly to vi

269 or replication in vitro and in the upper and lower respiratory tracts of hamsters: this was not influ

270 lture and viral replication in the upper and lower respiratory tracts of specific-pathogen-free (SPF)

271 ed for exclusive trafficking to the upper or lower respiratory tract or whether descendents from that

272 syncytial virus (RSV) is the most important lower respiratory tract pathogen of infants for which th

273 , an opportunistic pathogen of the upper and lower respiratory tracts, produces OMVs in vivo, but the

274 Confirmation of RSV infection in the lower respiratory tract provides prognostic information

275 in the relatively sterile environment of the lower respiratory tract, rather than in the upper respir

276 ricted 50-fold and 150-fold in the upper and lower respiratory tracts, respectively, of mice.

277 LRTI was defined as a positive lower respiratory tract sample with or without radiograp

278 Lower respiratory tract samples yield significantly high

279 sequencing techniques in the examination of lower respiratory tract samples.

280 e string test, a novel technique to retrieve lower respiratory tract samples; and fine needle aspirat

281 ric antibiotics for pneumonia treatment, and lower respiratory tract sampling to define pathogenic ba

282 (PMN) cells are regarded as indicative of a lower respiratory tract specimen.

283 spiratory viral panel on clinical and spiked lower respiratory tract specimens (LRTS).

284 g 401 adults with acute cough and at least 1 lower respiratory tract symptom not requiring immediate

285 be improved by case-finding in patients with lower respiratory tract symptoms and concordant long-ter

286 ulation, 6.2% to 13.4%) children experienced lower respiratory tract symptoms within 72 hours, includ

287 We have shown previously that lower respiratory tract symptoms, airflow obstruction, a

288 raphic and perinatal data, eczema, upper and lower respiratory tract symptoms, and family history of

289 ory of parental asthma, race, sex, upper and lower respiratory tract symptoms, season of birth, famil

290 of RV infections, and propensity to develop lower respiratory tract symptoms.

291 nza A(H7N9) could replicate in the upper and lower respiratory tract, the heart, the liver, and the o

292 ie the propensity of the virus to invade the lower respiratory tract under inflammatory conditions.

293 reat infections, most commonly involving the lower respiratory tract, urinary tract, or skin and soft

294 Lower respiratory tract virus infections are the major c

295 Upper and lower respiratory tract virus load, duration of virus sh

296 The lower respiratory tract was once thought to be a sanctua

297 rrespondingly, viral titers in the upper-and lower-respiratory tract were reduced only in piglets tha

298 ed carriage density and dissemination to the lower respiratory tract, while greatly constraining inna

299 esized that a specimen representative of the lower respiratory tract will contain smaller quantities

300 n of CD151 in IAV infection of the upper and lower respiratory tracts with H1N1 and H3N2 strains.